Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of biologics in psoriasis
Masahiro Kamata, Yayoi Tada
The Journal of Dermatology (2017) Vol. 45, Iss. 3, pp. 279-286
Closed Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter, Bruce Strober, Daniel H. Kaplan, et al.
Journal of the American Academy of Dermatology (2019) Vol. 80, Iss. 4, pp. 1029-1072
Closed Access | Times Cited: 730
Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis
Masutaka Furue
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5382-5382
Open Access | Times Cited: 269
Interleukin-17A and Keratinocytes in Psoriasis
Masutaka Furue, Kazuhisa Furue, Gaku Tsuji, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1275-1275
Open Access | Times Cited: 214
Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review
Masahiro Kamata, Yayoi Tada
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 5, pp. 1690-1690
Open Access | Times Cited: 180
Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis
Masutaka Furue, Akiko Hashimoto‐Hachiya, Gaku Tsuji
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 21, pp. 5424-5424
Open Access | Times Cited: 166
Gut–Skin Axis: Unravelling the Connection between the Gut Microbiome and Psoriasis
Angel Yun-Kuan Thye, Yi-Rou Bah, Jodi Woan‐Fei Law, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1037-1037
Open Access | Times Cited: 89
A New Insight into the Potential Role of Tryptophan-Derived AhR Ligands in Skin Physiological and Pathological Processes
Monika Szelest, Katarzyna Walczak, Tomasz Plech
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1104-1104
Open Access | Times Cited: 66
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
Alan Menter, Gerald G. Krueger, So Yeon Paek, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 2, pp. 385-400
Open Access | Times Cited: 61
Microneedle-mediated drug delivery for cutaneous diseases
Jian Chen, Ren Hui, Pan Zhou, et al.
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 45
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis
Kenneth B. Gordon, Richard Langley, Richard B. Warren, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 7, pp. 735-735
Open Access | Times Cited: 42
Crosstalk: keratinocytes and immune cells in psoriasis
Masahiro Kamata, Yayoi Tada
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 30
Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents
Anastasia Drakos, Tiago Torres, Ronald Vender
Pharmaceutics (2024) Vol. 16, Iss. 1, pp. 111-111
Open Access | Times Cited: 10
Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis
Kazuhisa Furue, Takamichi Ito, Masutaka Furue
Cytokine (2018) Vol. 111, pp. 182-188
Closed Access | Times Cited: 72
Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases
Shamarke Esse, K.J. Mason, Adèle C. Green, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 7, pp. 787-787
Open Access | Times Cited: 58
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy
Giuseppe Privitera, Daniela Pugliese, S. Onali, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 6, pp. 102832-102832
Closed Access | Times Cited: 55
Role of skin and gut microbiota in the pathogenesis of psoriasis, an inflammatory skin disease
Daniel K. Hsu, Maxwell A. Fung, Hung-Lin Chen
Medicine in Microecology (2020) Vol. 4, pp. 100016-100016
Open Access | Times Cited: 52
Potential Role of Probiotics in Ameliorating Psoriasis by Modulating Gut Microbiota in Imiquimod-Induced Psoriasis-Like Mice
Wenwei Lu, Yadan Deng, Zhifeng Fang, et al.
Nutrients (2021) Vol. 13, Iss. 6, pp. 2010-2010
Open Access | Times Cited: 49
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
Kenneth B. Gordon, Richard Langley, Richard B. Warren, et al.
British Journal of Dermatology (2023) Vol. 190, Iss. 4, pp. 477-485
Open Access | Times Cited: 18
Biologics and Psoriasis
Hee J. Kim, Mark Lebwohl
Dermatologic Clinics (2018) Vol. 37, Iss. 1, pp. 29-36
Closed Access | Times Cited: 52
Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances
Shuai Shao, Gang Wang, Emanual Maverakis, et al.
Drugs (2020) Vol. 80, Iss. 6, pp. 525-534
Open Access | Times Cited: 41
Mitochondrial Reactive Oxygen Species Are Essential for the Development of Psoriatic Inflammation
Soichi Mizuguchi, Kazuhito Gotoh, Yuya Nakashima, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 38
Deucravacitinib in the treatment of psoriasis
Tomás Estevinho, Ana Maria Lé, Tiago Torres
Journal of Dermatological Treatment (2022) Vol. 34, Iss. 1
Open Access | Times Cited: 24
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
Jolanta Pach, Kailyn Valido, Annika Belzer, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 595-607
Closed Access | Times Cited: 5
Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease
Kristian Reich, Richard B. Warren, Laura C. Coates, et al.
Journal of the European Academy of Dermatology and Venereology (2019) Vol. 34, Iss. 6, pp. 1161-1173
Open Access | Times Cited: 42
Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways
Husna Kadagothy, Shweta Nene, Etikala Amulya, et al.
European Journal of Pharmacology (2023) Vol. 947, pp. 175668-175668
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top